The stock of Oncternal Therapeutics Inc (ONCT) has gone down by -33.64% for the week, with a -52.35% drop in the past month and a -83.75% drop in the past quarter. The volatility ratio for the week is 12.10%, and the volatility levels for the past 30 days are 13.45% for ONCT. The simple moving average for the past 20 days is -44.62% for ONCT’s stock, with a -88.17% simple moving average for the past 200 days.
Is It Worth Investing in Oncternal Therapeutics Inc (NASDAQ: ONCT) Right Now?
Additionally, the 36-month beta value for ONCT is 1.27. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ONCT is 2.65M and currently, short sellers hold a 1.71% ratio of that float. The average trading volume of ONCT on November 26, 2024 was 96.67K shares.
ONCT) stock’s latest price update
The stock of Oncternal Therapeutics Inc (NASDAQ: ONCT) has decreased by -37.72 when compared to last closing price of 1.14.Despite this, the company has seen a loss of -33.64% in its stock price over the last five trading days. seekingalpha.com reported 2024-08-10 that Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q2 2024 Earnings Call August 8, 2024 5:00 PM ET Company Participants Richard Vincent – Chief Financial Officer Jim Breitmeyer – President and Chief Executive Officer Salim Yazji – Chief Medical Officer Conference Call Participants Carl Byrnes – Northland Capital Markets Kemp Dolliver – Brookline Capital Markets Operator Greetings and welcome to the Oncternal Therapeutics Second Quarter 2024 Financial Results Call. [Operator Instructions] As a reminder, this conference is being recorded.
Analysts’ Opinion of ONCT
Many brokerage firms have already submitted their reports for ONCT stocks, with Oppenheimer repeating the rating for ONCT by listing it as a “Outperform.” The predicted price for ONCT in the upcoming period, according to Oppenheimer is $14 based on the research report published on April 07, 2021 of the previous year 2021.
Northland Capital, on the other hand, stated in their research note that they expect to see ONCT reach a price target of $21. The rating they have provided for ONCT stocks is “Outperform” according to the report published on February 23rd, 2021.
ONCT Trading at -47.75% from the 50-Day Moving Average
After a stumble in the market that brought ONCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.60% of loss for the given period.
Volatility was left at 13.45%, however, over the last 30 days, the volatility rate increased by 12.10%, as shares sank -50.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -51.20% lower at present.
During the last 5 trading sessions, ONCT fell by -33.64%, which changed the moving average for the period of 200-days by -92.57% in comparison to the 20-day moving average, which settled at $1.2819. In addition, Oncternal Therapeutics Inc saw -93.38% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ONCT starting from Yazji Salim, who proposed sale 4,681 shares at the price of $1.07 back on Oct 14 ’24. After this action, Yazji Salim now owns shares of Oncternal Therapeutics Inc, valued at $5,009 using the latest closing price.
Wills Robert James, the Director of Oncternal Therapeutics Inc, purchase 3,086 shares at $8.96 during a trade that took place back on Apr 08 ’24, which means that Wills Robert James is holding 10,000 shares at $27,655 based on the most recent closing price.
Stock Fundamentals for ONCT
Current profitability levels for the company are sitting at:
- -21.57 for the present operating margin
- -10.18 for the gross margin
The net margin for Oncternal Therapeutics Inc stands at -20.74. The total capital return value is set at -3.93. Equity return is now at value -149.86, with -117.61 for asset returns.
Currently, EBITDA for the company is 2.23 million with net debt to EBITDA at 0.48. When we switch over and look at the enterprise to sales, we see a ratio of -6.47. The receivables turnover for the company is 4.85for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.39.
Conclusion
In conclusion, Oncternal Therapeutics Inc (ONCT) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
